FierceBiotech
Media & Internet · Missouri, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1001 NW Technology Dr, Lees Summit, Miss...Website
www.fiercebiotech.comRevenue
<$5 MillionIndustry
About FierceBiotech
Is FierceBiotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if FierceBiotech has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at FierceBiotech
Check out if FierceBiotech is spiking on competitors!
Funding: Get notified immidiatlly once FierceBiotech has new funding data
Click to see if FierceBiotech had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on FierceBiotech recently announced quarterly report
Product Launch: Get notified when FierceBiotech launches new products
FierceBiotech, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at FierceBiotech
Find 2 more new buyers
Compare Similar Companies to FierceBiotech
Compare insights from companies similar to FierceBiotech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
FierceBiotech
Company Profile Activity
Activity Insights
FierceBiotech is experiencing very low activity levels compared to other companies in the Media & Internet sector.
What does this means?
FierceBiotech is drawing exceptional interest within the Media & Internet industry, suggesting notable developments or strong market momentum, learn more about FierceBiotech.
FierceBiotech Tech Stack
A closer look at the technologies used by FierceBiotech
FierceBiotech News & Media
Fierce Pharma Asia—Astellas' stem cell therapy rethink; GSK's bullish ADC plan; Daiichi's OTC sale
Astellas will close a stem cell therapy site. GSK is pushing a Hansoh Pharma-partnered ADC into multiple phase 3 trials. | Astellas will close a stem cell therapy site. GSK is pushing a Hansoh Pharma-partnered ADC into multiple phase 3 trials. Daiichi Sankyo is selling its consumer health business unit for about $1.55 billion. And more.Questex’s Fierce Biotech Announces 2026 Fierce Outsourcing Award Winners, Honoring Excellence Across the Drug Development Ecosystem
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Questex’s Fierce Biotech today announces the winners of the 2026 Fierce Outsourcing Awards, recognizing the companies and teams driving innovation, performance, and partnership across the outsourced drug development landscape.Sensei Biotherapeutics Merges with Faeth Therapeutics, Secures $200M Funding
Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling winding down the company. But the biotech has found a new lease on life—and a new lead drug—via a merger with Faeth Therapeutics. Shareholders of privately owned Faeth will own 40.8% of the merged company, while Sensei's current shareholders will own 4.9%. The rest will be owned by investors that participated in a $200 million private placement.Questex’s Fierce Biotech Announces 2025 Fierce CRO Award Winners
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Questex’s Fierce Biotech today announces the winners of the second annual Fierce CRO Awards.
Top Media & Internet Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding FierceBiotech
Fierce Biotech is a leading source of news and reports focused on the biotechnology sector, covering topics such as clinical data, cell and gene therapy, and venture capital. The company provides insights into the latest developments in medtech, diagnostics, and biologics, catering to professionals in the life sciences industry. It also hosts event... Read More